Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NXTC
stocks logo

NXTC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-2.847
-42.14%
--
--
-2.460
-47.44%
--
--
-2.597
-77%
Estimates Revision
Stock Price
Go Up
up Image
+162.47%
In Past 3 Month
Wall Street analysts forecast NXTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXTC is 19.00 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast NXTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXTC is 19.00 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.730
sliders
Low
18.00
Averages
19.00
High
20.00
Current: 12.730
sliders
Low
18.00
Averages
19.00
High
20.00
Ladenburg
Neutral -> Buy
upgrade
$18
2025-11-07
Reason
Ladenburg
Price Target
$18
2025-11-07
upgrade
Neutral -> Buy
Reason
Ladenburg upgraded NextCure to Buy from Neutral with an $18 price target. The firm says SIM0505 has a "clear roadmap" to become a "best-in-class" antibody drug conjugate that targets CDH6 for the treatment of advanced solid tumors.
Piper Sandler
Edward Tenthoff
Overweight
downgrade
$36 -> $15
2025-07-15
Reason
Piper Sandler
Edward Tenthoff
Price Target
$36 -> $15
2025-07-15
downgrade
Overweight
Reason
Piper Sandler analyst Edward Tenthoff lowered the firm's price target on NextCure to $15 from $36 and keeps an Overweight rating on the shares. The firm notes NextCure exercised a 12-for-1 reverse stock split effective July 14th. Piper estimates NextCure now has 2.338 million shares outstanding and trades at an $11.5M market cap.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$3
2025-03-17
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$3
2025-03-17
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$4 → $3
2025-03-07
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$4 → $3
2025-03-07
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for NextCure Inc (NXTC.O) is -1.52, compared to its 5-year average forward P/E of -1.40. For a more detailed relative valuation and DCF analysis to assess NextCure Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.40
Current PE
-1.52
Overvalued PE
-0.22
Undervalued PE
-2.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.50
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.10
Undervalued EV/EBITDA
-0.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NXTC News & Events

Events Timeline

(ET)
2025-11-17
08:10:53
NextCure Completes $21.5 Million PIPE Financing Round
select
2025-11-12 (ET)
2025-11-12
08:22:57
NextCure sets price for 2.5 million shares at $8.52 in private placement
select
2025-11-05 (ET)
2025-11-05
16:57:31
NextCure Announces Q3 EPS of $3.22, Below Consensus Estimate of $3.98
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-17Newsfilter
NextCure Completes $21.5 Million PIPE Financing Ahead of Phase 1 POC Data Releases in Early 2026

  • Funding Announcement: NextCure, Inc. has successfully closed a private placement of common stock, raising approximately $21.5 million, which will extend its cash runway into the first half of 2027.

  • Use of Proceeds: The funds will be utilized for general working capital and to support proof of concept data readouts for two antibody drug conjugate programs, SIM0505 and LNCB74.

  • Private Placement Details: The offering involved the sale of 708,428 shares of common stock at $8.52 per share, along with pre-funded warrants for additional shares, all conducted under an exemption from the registration requirements of the Securities Act.

  • Company Overview: NextCure is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, particularly targeting patients who do not respond to existing treatments.

[object Object]
Preview
8.5
11-13NASDAQ.COM
NextCure Stock Rises 15% Following Private Placement News

  • Stock Performance: NextCure, Inc. (NXTC) shares rose 14.88% to $9.61 following the announcement of a private placement of approximately $21.5 million.

  • Funding Details: The company will issue 2,523,477 shares at $8.52 per share to institutional investors, with the funding expected to close around November 13, 2025.

  • Cash Runway Extension: The new funding will extend NextCure's cash runway into the first half of 2027 and support its antibody-drug-conjugate programs targeting CDH6 and B7-H4.

  • Trading Activity: The announcement led to unusually heavy trading volume for NXTC, with its stock price fluctuating between $2.65 and $9.61 over the past year.

[object Object]
Preview
4.5
07-25Benzinga
US Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus

  • Market Overview: U.S. stock futures showed mixed performance following a volatile trading session, with President Trump pressuring the Federal Reserve for interest rate cuts ahead of their upcoming decision on July 30. Analysts noted a bullish divergence in market breadth despite recent declines in certain sectors.

  • Company Highlights: Alphabet Inc. reported strong quarterly results while Tesla's performance fell short of expectations. Notable stock movements included Intel's significant drop after announcing layoffs, and several companies like NextCure and Linkhome Holdings saw substantial gains due to positive developments or IPOs.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is NextCure Inc (NXTC) stock price today?

The current price of NXTC is 12.73 USD — it has increased 5.77 % in the last trading day.

arrow icon

What is NextCure Inc (NXTC)'s business?

NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.

arrow icon

What is the price predicton of NXTC Stock?

Wall Street analysts forecast NXTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXTC is 19.00 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is NextCure Inc (NXTC)'s revenue for the last quarter?

NextCure Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is NextCure Inc (NXTC)'s earnings per share (EPS) for the last quarter?

NextCure Inc. EPS for the last quarter amounts to -3.22 USD, decreased -34.95 % YoY.

arrow icon

What changes have occurred in the market's expectations for NextCure Inc (NXTC)'s fundamentals?

The market is revising No Change the revenue expectations for NXTC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 162.47%.
arrow icon

How many employees does NextCure Inc (NXTC). have?

NextCure Inc (NXTC) has 43 emplpoyees as of December 05 2025.

arrow icon

What is NextCure Inc (NXTC) market cap?

Today NXTC has the market capitalization of 66.24M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free